No-deal Brexit could see EU patients miss out on cancer medication, says drugs firm AstraZeneca A no-deal Brexit could mean patients in the EU will not be able to receive medicines from the UK, a pharmaceutical giant has said.
AstraZeneca warned patients might miss out on drugs if the company does not “prepare well” for the possibility of a no deal.
The company, which has its research headquarters in Cambridge, manufactures medicines for treating cancer, heart and lung problems. The Independent
AstraZeneca warned patients might miss out on drugs if the company does not “prepare well” for the possibility of a no deal.
The company, which has its research headquarters in Cambridge, manufactures medicines for treating cancer, heart and lung problems. The Independent
No comments:
Post a Comment